Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Mhb Labs Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being reviewed by 1 distinct examiner, which points to a very narrow scope of active prosecution. The portfolio is further characterized by its presence in 1 distinct art unit, centralizing the technical review process for the company's applications.
MACH, ANDRE is the busiest examiner for this entity, holding responsibility for the 1 busiest examiner pending action. With only 1 distinct examiner to interface with, the company can maintain a direct and consistent line of communication regarding its intellectual property. This 1:1 relationship between the pending action and the examiner reduces the complexity often found in larger, more distributed portfolios.
The Biotechnology & Pharmaceuticals area typically requires rigorous examination, and here, that process is focused on 1 pending office action. The fact that only 1 distinct art unit is involved means that the company does not have to navigate different divisional interpretations of patent law. This allows for a concentrated effort to resolve the 1 pending office action under the guidance of MACH, ANDRE.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MACH, ANDRE | 1 | 44.9% | +51.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17281902 | EXTENDED RELEASE FORMULATIONS OF HUMAN CHORIONIC GONADOTROPIN (HCG) | MACH, ANDRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17281902 | EXTENDED RELEASE FORMULATIONS OF HUMAN CHORIONIC GONADOTROPIN (HCG) | MACH, ANDRE | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17281902 | EXTENDED RELEASE FORMULATIONS OF HUMAN CHORIONIC GONADOTROPIN (HCG) | MACH, ANDRE | 1615 | §102§103Other | Non-Final OA | — | Pending | Mar 31, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial